Topic Listing for ImmunoGen

Abgenix Inc Ability Current Capital Resources Anticipated Future Collaborator
Acceptance Rent New Directory Name Accounting Revenue Arrangements Multiple Elements
Accounting Stock Based Compensation Accounting Stock Issued Employees
Additional Anticancer Therapeutics Additional Representations Immunogen Further Represents Warrants Sanofi-aventis Effective
Administrator Affiliate
Against Immunogen Pending Immunogens Knowledge Threatened Invalidate Seek Agreement
Agreement Shall Governed Construed Accordance Laws State New Agreements
Amendment Amendment Collaboration License Agreement
Amendment Lease Amendment License Agreements
Amendment Partial Termination Lease Amendment Stock Option Agreements
Amendments Articles Incorporation Bylaws Change Amendments By-laws
Amgen Amgen Inc
Amgen Inc Formerly Abgenix Annual Executive Bonus Program
Annual Meetings Stockholders Anti-igf-1r Antibody
Antibody Requirements Clinical Materials Manufactured Significantly Higher Estimated Antibody-may Compound Conjugate Means Containing Antibody
Appendices Appendix
Application Thereof Invalid Illegal Unenforceable Being Intent Parties Arrangements Multiple Elements
Attend Vote Meeting Audit Committee
Audit Committee Report Audit Fees
Audit-related Fees Ave1642
Ave1642 Additional Multi-arm Trial Initiated Ave1642 Clinical Findings Reported
Ave9633 Aventis Pharmaceuticals Inc
Base Salaries Base Salaries Executive Officers
Base Salary Basis Presentation
Bayer Healthcare Bayer Healthcare Ag-
Beneficial Ownership Reporting Compliance Benefits
Biib015 Biogen Idec
Biogen Idec Biib015 Biogen Idec Inc
Biogen Idec Inc- Bioinvent International
Biotest Biotest Ag-
Biotest Bt062 Biotest Tap Compound
Bivatuzumab Mertansine Board
Board Directors Board Directors Recommends Vote
Boehringer Ingelheim Boehringer Ingelheim International Gmbh
Bonus Awards Bt-062
Business Business Goals Strategy
Business Means Banking Institutions New York Open C242
Cafeteria Pro Rata Share Calendar 2007 Individual Election Form
Cambridge 2005 Cambridge 2006
Cambridge 2007 Cambridge 2008
Capital Stock Carol Hausner
Cash Equivalents Cash Flows
Cash Incentive Awards Cause
Centocor Centocor Inc
Certain Agreements Certain Factors Affect Future Results Operations
Certain Matters Pertaining Stockholder Business Nominations Certain Relationships Related Transactions
Certificates Equivalents Country Territory Applicable Licensed Patent Rights Certifications
Certifications 302 Certifications 906
Change Control Change Vote After Already Voted
Changes Internal Control Over Financial Reporting Changes Internal Controls
Changes Securities Proceeds Clinical Trials Collaborative Partners Product Candidates Lengthy Expensive
Clinical Trials Process Clinical Trials Product Candidates Lengthy Expensive Outcome Uncertain
Closing Conditions Closing Deliveries
Collaboration License Agreement Collaboration Portfolio Amendment Effective Date
Collaboration Product Candidates Collaboration Sanofi-aventis
Collaborations Update Collaborative Partners Fail Perform Obligations Agreements Determine Not
Collaborative Partners Fail Perform Obligations Agreements Them Determine Collaborative Partners Product Candidates Remain Subject Ongoing Regulatory
Collaborative Partners Requirements Clinical Materials Manufactured Significantly Lower Collaborative Partners Subject Extensive Government Regulations Not Able
Collaborators Product Candidates Not Gain Market Acceptance Business Collaborators Requirements Clinical Product Manufacture Them Significantly Lower
Commitments Contingencies Committee
Committees Board Directors Meetings Committees Board Directors Meetings Attendance
Common Preferred Stock Common Stock Par Value
Common Stock Reserved Communicate Immunogens Directors
Compensation Chief Executive Officer Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Interlocks Insider Participation Decisions
Compensation Committee Report Compensation Committee Report Executive
Compensation Directors Compensation Discussion Analysis
Compensation Philosophy Compensation Philosophy Objectives
Compensation Policy Components Competition
Components Compensation Composition
Compound Certain B-cell Malignancies Comprehensive Loss
Computation Net Loss Per Common Share Condominium Conversion Contingency
Conduct Indemnification Proceedings Confidentiality
Consent Independent Registered Public Accounting Firm Contact
Contacts Contractual Obligations
Controls Procedures Corporate Governance Nominating Committee
Creation Direct Financial Obligation Off-balance Sheet Arrangement Critical Accounting Policies
Current Executive Officers Currently Rely Third-party Manufacturer Commercial Production Experience Produce
Cytovance Biologics Cytovance Biologics Llc
Daniel Junius President Chief Operating Officer Date Report Earliest Event Reported 2007 Immunogen Inc
Deferred Share Unit Definitions
Delivery Executives Written Requests Payment Accompanied Such Evidence Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Depend Key Personnel Continue Attract Retain Employees Consultants
Depend Small Number Collaborators Substantial Portion Revenue Loss Derivatives
Determine Executive Compensation Development Commercialization Licensed Products
Development License Agreement Diosynth Rtp
Diosynth Rtp Inc Director Compensation 2008
Director Compensation 2009 Directors
Directors Compensated Disability
Disclosure Controls Procedures Disclosures Segments Enterprise Related Information
Dispute Resolution Dm1 Specifications
Dm4 Specifications Documents Incorporated Reference
Drug Conjugate Composition Formulation Drug Development Process
Duration Effectiveness Period
Eighth Amendment Lease Election Form
Elements Total Compensation Employee
Employee Benefit Plans Employee Benefits
Employee Director Consultant Equity Incentive Plan Amended Restated Employees
Employment Agreements Employment Contracts Termination Change Control Agreements
Entire Agreement Choice Law Enforceability Entry Material Definitive Agreement
Equity Awards Equity Compensation
Equity Compensation Plan Information Equity Compensation Plans
Equity Incentive Plan Estimated Materials Requirements Stages
Estimates Estoppels
Evaluation Disclosure Controls Procedures Event
Event Date Event Such Force Majeure Party Affected Shall Reasonable
Exclusions Operating Expenses Exclusive Target Options
Exclusively Licensed Respect Such Target Sanofi-aventis Terms Subject Executed
Executive Compensation Executive Compensation Determinations 2009
Executive Officers Executive Severance Agreement
Exhibits Exhibits Financial Statement Schedules
Expand Study 003 Maximum Tolerated Dose Imgn901 Established Explanatory
Extent Permitted Applicable Law Hereby Absolutely Unconditionally Irrevocably Face Product Liability Risks Not Able Obtain Adequate
Factors Fully Described Immunogens Annual Report Form 10-k Fair Market Value
Fair Value Financial Instruments Federal Income Tax Consequences
Fifth Amendment Lease Filing Prosecution Maintenance Patent Rights
Financial Guidance Financial Instruments Concentration Credit Risk
Financial Results Financial Statements Exhibits
Financial Statements Materiality Financial Terms
Fixing Number Members Board Directors Fluctuations Quarterly Revenue Operating Results Cause Stock Price
Forced Litigate Undertake Other Proceedings Order Enforce Intellectual Foreign Currency Exchange Risk
Foreign Regulation Form 10-k
Form 10-q Form Exclusive License Agreement
Form Lock-up Agreement Form Royalty Report
Forward-looking Statements Gene Family
Genentech Genentech Inc
Genentech T-dm1 Genentech-
General General Administrative Expenses
General Information General Information Annual Meeting
Glaxosmithkline Plc Gmp-related Activities
Good Faith Efforts Incorporate Comments Such Other Party Good Standing Laws Jurisdiction Organization Requisite Power Authority
Governance Nominating Committee Governing Law
Government Regulation Product Approval Grant Rights
Grants Plan-based Awards Hazardous Materials Business Claims Relating Improper Handling Storage
Headings Subsection Inserted Convenience Reference Only Not Form History Operating Losses Expect Incur Significant Additional
Hold Position Cfo Subsidiary Reduction Cfos Annual Base Hold Position Evp Subsidiary Reduction Evps Annual Base
Hold Position Svp Subsidiary Reduction Svps Annual Base Huc242-dm4
Huc242-dm4 Evaluation Gastric Cancer Preclinical Findings Huc242-dm4 Phase Evaluation Updated Clinical Findings
Hun901-dm1 I-stockholders
Ii-officers Directors Iii-board Directors
Imgn242 Imgn242 Findings Reported
Imgn242 Huc242-dm4 Imgn242 Phase Ongoing
Imgn388 Imgn388 Biib015 Bt-062 Most Recent Entries Clinic
Imgn388 Bt-062 Biib015 Imgn388 Sar3419 Biib015 Bt-062
Imgn901 Imgn901 Encouraging Phase Findings Reported
Imgn901 Hun901-dm1 Immunogen Code Corporate Conduct
Immunogen Inc Immunogen Inc 2006 Employee Director Consultant Equity Incentive
Immunogen Inc Announces Addition Stephen Mccluski Board Directors Immunogen Inc Announces Ceo Succession Plan
Immunogen Inc Announces Clinical Data Reported Asco Immunogen Inc Announces Sanofi-aventis Group Extended Research Collaboration
Immunogen Inc Index Consolidated Financial Statements Immunogen Inc Reports 2009 Financial Results
Immunogen Inc Reports Initial Phase Findings Hun901-dm1 Anticancer Immunogen Inc Schedule Ii-valuation Qualifying Accounts
Immunogen Inc Table Contents Immunogen Policy Regarding Director Attendance Annual Meetings Shareholders
Immunogen Soliciting Proxies Immunogen Technology Improvements
Immunogen Written Policy Governing Related Person Transactions Immunogens Executive Officers
Immunogens Huc242-dm4 Hun901-dm1 Product Candidates Immunogens Huc242-dm4 Product Candidate
Immunogens Hun901-dm1 Product Candidate Immunogens Maytansinoid Tap Technology
Immunogens Tap Technology Impact Linker Selection Activation Tap Compounds
Impairment Disposal Long-lived Assets Impairment Long-lived Assets
Improved Cytotoxic Agents Comprising New Maytansinoids Dm4 Improvement
Improvement Means Enhancement Modification Licensed Technology Patent Rights In-licenses
Inability License Parties Proprietary Technologies Processes Connection Development Incidence Relevant Cancers
Include Not Income Taxes
Incur Substantial Costs Result Litigation Other Proceedings Relating Indemnification
Indemnification Liability Indemnified Party
Indemnified Party Unless Such Settlement Includes Unconditional Release Indemnifying Party
Independence Independent Auditors
Index Index Consolidated Financial Statements
Index Exhibits Industrial Research Limited
Information Directors Infringement
Inspection Access Changes Building Facilities Inspectors
Intellectual Property Rights Interest Income
Internal Control Over Financial Reporting Internal Control-integrated Framework
Internet Telephone Vote Authorizes Named Proxies Shares Same Introduction
Inventories Inventory
Investment Income Net Investment Marketable Securities
Iso Issuer Free Writing Prospectus
Iv-executive Officers John Lambert Phd
John Lambert Phd Executive Vice President Research Development Landlords Rights Remedies
Laureate Pharma Laureate Pharma Inc
Lead Director Lease Agreement
Leases Legal Proceedings
License Agreement License Agreement Shall Exclusively Licensed Respect Such Target
License Grants Limitations Effectiveness Controls
Liquidity Capital Resources List Option Agreements Covering Affected Options
Lock-up Signatories Looking Statements Provided Private Securities Litigation Reform Act
Losses Managements Annual Report Internal Control Over Financial Reporting
Managements Discussion Analysis Financial Condition Results Operation Manufacturing Operations
Market Opportunity Market Price Common Stock Related Stockholder Matters
Market Registrants Common Equity Related Stockholder Matters Issuer Marketable Securities
Marketing Product Being Developed Proposed Material Features 2006 Plan
Materials Being Available Meeting Attendance
Meeting Directions Meeting Information
Meetings Methods Production Ansamitocins Fermentation Process
Milestone Payments Millennium Pharmaceuticals Inc
Minimis Mintz Levin Cohn Ferris Glovsky Popeo
Miscellaneous Mln2704
Mmuno Inc Morphosys
Mta Shall Mean Certain Material Transfer Evaluation Agreement Much Stock Immunogens Directors Executive Officers Own
Naked Antibodies Development Sanofi-aventis Nature Business Plan Operations
Net Realized Gains Losses Investments Net Realized Losses Gains Investments
Net Realized Losses Investments Net Sales Licensed Product Calendar
New Drugs Serious Life Threatening Illnesses New Drugs Serious Life-threatening Illnesses
New Plan Benefits Nitro-pyridyl Linker
Nominees Nominees Board Selected
Non-disparagement Non-employee Director
Non-employee Director Compensation Deferred Share Unit Plan Non-employee Director Stock Plan
Non-employee Directors Compensated 2008 Non-employee Directors Compensated 2009
Non-exclusive Research License Option Exclusive Not Intend Pay Cash Dividends Common Stock
Notice Notice Annual Meeting Shareholders Held 2005
Notice Annual Meeting Shareholders Held 2006 Notice Annual Meeting Shareholders Held 2007
Notice Annual Meeting Shareholders Held 2008 Notice Annual Meeting Shareholders Held 2009
Notwithstanding Foregoing Unvested Deferred Stock Units Shall Vest Now Therefore
Number 0-17999 Obtain Information Immunogens Executive Officers
Off-balance Sheet Arrangements Often Did Board Committees Meet 2008
Often Did Board Committees Meet 2009 Only Conjugate Manufacturing Facility Prolonged Significant Disruption Impair
Only In-house Pilot Manufacturing Facility Prolonged Significant Disruption Option Agreement Means Between Parties Dated 2006
Option Exercises Option Exercises Stock Vested
Option License Agreement Options Exercised
Orlando 2005 Orphan Drug Designation
Other Accrued Liabilities Other Agreements
Other Agreements Parties Other Collaborative Agreements
Other Compounds Other Compounds Development
Other Current Accrued Liabilities Other Events
Other Expense Income Other Expense Income Net
Other Fees Other Income
Other Income Expense Other Income Net
Other Information Other Licenses
Other Loss Income Other Potential Products
Other Stock-based Awards Other Temporary Impairment
Other-than-temporary Impairments Out-licenses Collaborations
Outlicenses Collaborations Outstanding Equity Awards 2008 Year-end
Outstanding Options Restricted Stock Other Similar Rights Held Overtime Hvac
Overview Owns Stock
Part Participant
Party Exercise Right Hereunder Manner Impair Such Party Infringement
Party Royalty Offset Patent Filing
Patent Filing Prosecution Maintenance Patent Term Restoration Marketing Exclusivity
Patents Trademarks Trade Secrets Payment Royalties
Payments Person
Plan Please Fill Reverse Side Mail Enclosed Envelope
Polypeptide Sequences Portions Omitted Been Filed Separately Secretary Pursuant Application
Portions Omitted Indicated Been Filed Separately Secretary Pursuant Possible Effects Proposed Amendment
Post-approval Requirements Potential Payments Termination Change Control
Potential Payments Termination Employment Following Change Control Without Potential Payments Termination Employment Without Cause Not Disability
Potential Sale Additional Shares Common Stock Cause Price Pre-approval Policies Procedures
Preclinical Clinical Testing Press Release Includes Forward-looking Statements Based Managements Current
Pricing Information Principal Accountant Fees Services
Principles Consolidation Process Product Development
Product Candidates Product Candidates Remain Subject Ongoing Regulatory Review Even
Product Candidates Those Collaborative Partners Not Gain Market Product Candidates Those Collaborators Not Gain Market Acceptance
Program Technology Project Stages Key Deliverables
Properties Property Equipment
Provisions Supply Agreements Proxy Materials Available
Proxy Solicited Board Directors Immunogen Inc Annual Meeting Purchase Dedicated Equipment
Purchase Obligations Purchase Sale
Purpose Purpose Proposed Amendment
Pursuant Quantitative Qualitative Disclosure Market Risk
Quantitative Qualitative Disclosures Market Risk Raw Materials Manufacturing
Recent Accounting Pronouncements Recent Corporate Highlights
Recent Highlights Reclassifications
Recommendation Reduction Ceos Target Annual Bonus Compared Set Previous
Reduction Securities References
Regarding Availability Proxy Materials Registration
Registration Rights Agreement Regulation Disclosure
Regulatory Matters Reimbursement
Release Claims Rely Single Source Suppliers Manufacture Primary Component Dm1
Rely Single Source Suppliers Manufacture Primary Component Small Rely Third-party Manufacturer Commercial Production Experience Produce Cell-killing
Remainder Page Intentionally Left Blank Rent
Report Audit Committee Report Independent Registered Public Accounting Firm
Report Independent Registered Public Accounting Firm Internal Control Reporting Comprehensive Income
Representations Warranties Representations Warranties Covenants
Request Copy Materials Requirements Scale
Requires Research
Research Development Research Development Costs
Research Development Expenses Research Development Spending
Responsibilities Duties Responsibility Sole Cost Expense Manufacture Licensed Products Including
Restricted Cash Restricted Stock
Results Operation Financial Condition Results Operations Financial Condition
Revenue Recognition Revenue Recognition-change Accounting Principle
Review Approval Processes Risk Factors
Rule 24b-2 Securities Exchange Act 1934 Amended Sale Common Stock
Sanofi Sanofi-aventis
Sanofi-aventis Ave1642 Ave9633 Sar3419 Sanofi-aventis Formerly Aventis
Sar3419 Sar3419 Expanding Clinical Program
Sar566658 Sar650984
Scale Agreement Scale-up Activities
Schedule Schedule 14a
Securities Purchase Agreement Securities Registered Pursuant Act
Security Ownership Certain Beneficial Owners Management Related Stockholder See
Segment Information Separation Employment
Severance Agreement Severance Agreements
Severance Compensation Termination Protection Severance Pay
Shall Time Obligated Additional Registration Statements Cover Registrable Share-based Payment
Shareholder Communications Board Shareholder Communications Directors
Shareholder Proposals Other Matters Shares
Sidney Street Cambridge 02139 Sidney Street Cambridge Massachusetts 02139 617-995-2500
Signature Page Follows Signatures
Significant Collaborative Agreements Significant Research Development Agreements
Sits Board Directors Sixth Amendment Lease Bobson 333 Llc Immunogen Inc
Smcc Conjugates Società Italiana Corticosteroidi Srl Sicor
Special Meetings Stockholders Stage
Statement Cash Flows Stock Based Compensation
Stock Compensation Stock Option Plan
Stock Options Stock Plan
Stock Price Fluctuate Significantly Results Announced Collaborators Cause Stock Right
Stock-based Award Stock-based Compensation
Stockholder Communications Directors Stomach Cancer
Submission Matters Vote Security Holders Subsections 1350 Chapter Title United States Code
Subsequent Event Subsequent Events
Subsidiaries Success Milestone
Such Fraudulent Misrepresentation Sughrue Mion Pllc
Summary Annual Executive Bonus Program Summary Other Material Features 2006 Plan
Summary Reasons Amendment 2006 Plan Surviving Provisions Termination Expiration Agreement Reason Shall Without
Survivor T-dm1
Table Contents Tap Compounds Development Sanofi-aventis
Tap Technology Tap Technology Not Produce Safe Effective Commercially Viable
Tax Deductibility Compensation Tax Fees
Team Communication Technology Transfer Immunogen Activities
Technology Update Term Agreement Shall Commence Effective Date Continue
Term Termination Termination Agreement Terminated Time Either Party Follows
Termination Date Termination Immunogen 721 Agreement Terminated Pursuant
Termination Material Definitive Agreement Termination Notice Severance Compensation
Third-party Trademarks Total Fte Requirement Immunogen
Trastuzumab-dm1 Trastuzumab-dm1 Broad Clinical Program Being Implemented
Trastuzumab-dm1 T-dm1 Travel Expenses
Treatment Confidential Information Tumor-activated Prodrug Tap Technology
Unable Compete Successfully Unable Establish Manufacturing Capabilities Necessary Develop Commercialize Collaborative
Unable Establish Manufacturing Capabilities Necessary Develop Commercialize Potential Unable Establish Sales Marketing Capabilities Necessary Successfully Commercialize
Unable Obtain Additional Funding Needed Delay Scale Back Unable Protect Intellectual Property Rights Adequately Value Technology
Unbilled Revenue Unfavorable Pricing Regulations Third-party Reimbursement Practices Healthcare Reform
Unregistered Sales Equity Securities Proceeds Update
Update Collaboration Product Candidates Update Immunogen Collaborations
Update Immunogen Product Candidate Huc242-dm4 Update Immunogen Product Candidate Hun901-dm1
Update Immunogen Product Candidates Update Partner Achievements
Updated Financial Guidance V-capital Stock
Vernalis Formerly British Biotech Plc Vernalis Plc
Vi-miscellaneous Provisions Vii-amendments
Vitro Vivo
Vote Important Please Return Proxy Promptly Vote Internet
Vote Person Vote Proxy
Vote Shares Held Broker Votes Counted
Wall Street Journal Waltham 2008
Waltham 2009 Warning Forward-looking Statements
Warrants Washington 20549
Webcast Information What Audit Committees Pre-approval Policy
What Committees Board Established What Constitutes Quorum Meeting
What Discretion Broker Vote Shares Held Street Name What Fees Independent Registered Public Accounting Firms Services
What Voting Whereas
Whether Plan Attend Annual Meeting Not Please Complete Winter Street Waltham 02451
Witness Whereof Writing Sanofi-aventis Shall Scheduled Immunogen Times Mutually Convenient
Wwwimmunogencom Yield
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki